Bayer Signs a Research and Development Collaboration with Arvinas for its PROTAC Technology
Shots:
- Arvinas to get ~$60M including upfront- equity investments- R&D funds and $685M milestones and royalties on sales of products. Bayer to get rights for the therapies developed in collaboration using Arvinas’s PROTAC Technology
- The focus of the collaboration is to develop therapies using Arvinas’ PROTAC protein degrader technology in cardiovascular- oncology- and gynecological disorders
- Arvinas’ PROTAC (Proteolysis-Targeting Chimera) is a protein degrader technology used for harnessing body’s own natural protein disposal system and further degrades disease-causing proteins into amino acids
Ref: Bayer | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com